The nanotechnology sector is experiencing an exponential growth period with over 100 products containing manufactured nanoparticles entering the markets every year. Ensuring growth of the sector needs to be balanced against the imperative of protecting both human and environmental safety. This project will develop new methodological and conceptual avenues to close the gap between innovation in nanotechnology and risk assessment. This will be achieved by developing and validating high-throughput in vitro toxicity screening platforms for manufactured nanoparticles. Our approach is based on advanced lab-on-a-chip microfluidic technologies. The predictive power of our platform will be refined and optimised via ex vivo and in vivo models.